ABSTRACT
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of myeloid precursors arrested in their maturation, creating a diverse disease entity with a wide range of responses to historically standard treatment approaches. While significant progress has been made in characterizing and individualizing the disease at diagnosis to optimally inform those affected, progress in treatment to reduce relapse and induce remission has been limited thus far. In addition to a brief summary of the factors that shape prognostication at diagnosis, this review attempts to expand on the current therapies under investigation that have shown promise in treating AML, including hypomethylating agents, gemtuzumab ozogamicin, FLT3 tyrosine kinase inhibitors, antisense oligonucleotides, and other novel therapies, including aurora kinases, mTOR and PI3 kinase inhibitors, PIM kinase inhibitors, HDAC inhibitors, and IDH targeted therapies. With these, and undoubtedly many others in the future, it is the hope that by combining more accurate prognostication with more effective therapies, patients will begin to have a different, and more complete, outlook on their disease that allows for safer and more successful treatment strategies.
Subject(s)
Humans , Aminoglycosides , Antibodies, Monoclonal, Humanized , Elafin , Genetics , Histone Deacetylase Inhibitors , Therapeutic Uses , Isocitrate Dehydrogenase , Leukemia, Myeloid, Acute , Drug Therapy , Genetics , Pathology , Proto-Oncogene Proteins c-pim-1 , Metabolism , TOR Serine-Threonine Kinases , GeneticsABSTRACT
<p><b>OBJECTIVE</b>To observe the therapeutic effect of Chinese compound, Changlu Enema (CE), on immune ulcerative colitis (UC) in mice.</p><p><b>METHODS</b>Mice were randomly divided into the normal group, the model group, the CE high dose (CE-H) and low dose (CE-L) group and the salicylazosulfapyridine (SASP) group. All mice, except those in the normal group, were made into UC model by colonic mucosa protein immunization. After 21 days of medication, the changes of UC activity index and body weight in mice were observed, and the condition of colonic inflammation and histomorphological changes in colonic tissue were observed also.</p><p><b>RESULTS</b>UC activity index was lower and body weight was higher in the two CE groups than those in the model group respectively, showing significant difference (P < 0.05 or P < 0.01); pathological examination showed the pathological changes and inflammatory response in colonic tissue were relieved significantly after treatment, and the improvement in the CE-H group was better than that in the SASP group.</p><p><b>CONCLUSION</b>TCM compound CE is markedly effective in treating UC rats.</p>
Subject(s)
Animals , Male , Mice , Administration, Rectal , Colitis, Ulcerative , Drug Therapy , Allergy and Immunology , Colon , Pathology , Drugs, Chinese Herbal , Therapeutic Uses , Phytotherapy , Random Allocation , Treatment OutcomeABSTRACT
<p><b>UNLABELLED</b>(GPL) in patients suffered from chronic atrophic gastritis (CAG) differentiated as Pi-deficiency with damp-heat retention and blood stasis in TCM Syndrome differentiation.</p><p><b>METHODS</b>Sixty-eight patients fitting to the admission criteria were randomly divided into two groups, 36 patients were treated with KWG in the treated group and 32 were treated with Weifuchun in the control group, all were treated for 2 treatment courses (12 weeks as one course).</p><p><b>RESULTS</b>The curative effects on gastroscopy and pathologic changes in the treated group were significantly superior to those in the control group (P < 0.05). The comparison of clinical efficacy, symptom improvement, anti-Helicobactor pylori effect between the two groups was insignificantly different (P > 0.05).</p><p><b>CONCLUSION</b>KWG is an effective drug for GPL.</p>